Sarah Elizabeth Yentz, MD

home / authors / sarah-elizabeth-yentz-md

Articles

Sarah Elizabeth Yentz, MD

Dr Yentz on Treatment Decisions in Favorable-Risk RCC

Sarah Elizabeth Yentz, MD
October 18th 2023

Sarah Elizabeth Yentz, MD, discusses treatment considerations in patients with favorable-risk renal cell carcinoma.

Read More

Sarah Elizabeth Yentz, MD

Dr Yentz on Treatment Decisions for Patients With Kidney Cancer

Sarah Elizabeth Yentz, MD
August 17th 2023

Sarah Elizabeth Yentz, MD, discusses how she decides between an immunotherapy agent plus a TKI combination vs 2-agent immunotherapy for patients with renal cell carcinoma.

Read More

Sarah Elizabeth Yentz, MD

Dr. Yentz on Translating Data to Real-World Clinical Practice in RCC

Sarah Elizabeth Yentz, MD
January 18th 2022

Sarah Elizabeth Yentz, MD, discusses translating data to real-world clinical practice in renal cell carcinoma.

Read More

Sarah Elizabeth Yentz, MD

Dr. Yentz on Unmet Needs in Metastatic RCC

Sarah Elizabeth Yentz, MD
November 11th 2021

Sarah Elizabeth Yentz, MD, discusses unmet needs in metastatic renal cell carcinoma.

Read More

Sarah Elizabeth Yentz, MD,

Dr. Yentz on Navigating Frontline Treatment Selection in RCC

Sarah Elizabeth Yentz, MD
November 1st 2021

Sarah Elizabeth Yentz, MD, discusses navigating frontline treatment selection in renal cell carcinoma.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need